首页 | 本学科首页   官方微博 | 高级检索  
     检索      


Sample size re-estimation for survival data in clinical trials with an adaptive design
Authors:Togo Kanae  Iwasaki Manabu
Institution:Clinical Statistics, Pfizer Japan Inc., Tokyo, Japan. kanae.togo@pfizer.com
Abstract:In clinical trials with survival data, investigators may wish to re-estimate the sample size based on the observed effect size while the trial is ongoing. Besides the inflation of the type-I error rate due to sample size re-estimation, the method for calculating the sample size in an interim analysis should be carefully considered because the data in each stage are mutually dependent in trials with survival data. Although the interim hazard estimate is commonly used to re-estimate the sample size, the estimate can sometimes be considerably higher or lower than the hypothesized hazard by chance. We propose an interim hazard ratio estimate that can be used to re-estimate the sample size under those circumstances. The proposed method was demonstrated through a simulation study and an actual clinical trial as an example. The effect of the shape parameter for the Weibull survival distribution on the sample size re-estimation is presented.
Keywords:interim analysis  hazard ratio  sample size re‐estimation  survival data
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号